The purpose of this study is to examine hematopoietic neoplasms with 9p24/JAK2 rearrangement including neoplasms associated with t(8;9)(p22;p24)/PCM1-JAK2 fusion neoplasm as well as cases with translocations involving 9p24/JAK2 and other partner genes. From seven large medical centers, we identified ten patients with t(8;9)(p22;p24) /PCM1-JAK2 and 3 with t(9p24;v)/JAK2 at diagnosis. Majority of the cases showed myeloproliferative neoplasm (MPN) associated features (n = 7) characterized by variable degrees of eosinophilia, myelofibrosis, frequent proliferations of early erythroblasts in bone marrow and extramedullary sites, and infrequent/absent somatic mutations. Other less common presentations included myelodysplastic syndromes (MDS) or MDS/MPN (one each). Four patients presented with B-lymphoblastic leukemia (B-ALL), and of them, two patients with t(8;9)(p22;p24.1) were proven to be B-lymphoblastic crisis of MPN; and the other two cases with t(9p24;v) both were de novo B-ALL, BCR-ABL1-like (Ph-like). We show that the hematopoietic neoplasms with 9p24/JAK2 rearrangement are extremely rare, and most of them are associated with t(8;9)(p22;p24)/PCM1-JAK2, a recent provisional World Health Organization entity under “myeloid/lymphoid neoplasm with a specific gene rearrangement”. Cases of t(8;9)(p22;p24)/PCM1-JAK2, though heterogeneous, do exhibit some common clinicopathological characteristic features. Cases with t(9p24;v)/JAK2 are extremely rare; while such cases with a MPN presentation may resemble t(8;9)(p22;p24.1)/PCM1-JAK2, B-ALL cases presenting de novo B-ALL might belong to Ph-like B-ALL.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev. 2007;17:8–14.

  2. 2.

    Santos FP, Verstovsek S. JAK2 inhibitors: what’s the true therapeutic potential? Blood Rev. 2011;25:53–63.

  3. 3.

    Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol. 2014;166:809–17.

  4. 4.

    Stewart K, Carstairs KC, Dube ID, Keating A. Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia. Am J Hematol. 1990;34:59–63.

  5. 5.

    Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22; p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662–7.

  6. 6.

    Rumi E, Milosevic JD, Selleslag D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015;94:1927–8.

  7. 7.

    Bain BJ, Horny H-P, Arber DA, Tefferi A, Hasserjian RP. Myeloid/lymphoid neoplasms with eosinophilia and rearrangements of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Revised. 4th edn. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 72–9.

  8. 8.

    Tang G, Goswami RS, Liang CS, et al. Isolated del(5q) in patients following therapies for various malignancies may not all be clinically significant. Am J Clin Pathol. 2015;144:78–86.

  9. 9.

    Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.

  10. 10.

    Wang SA, Tam W, Tsai AG, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016;29:854–64.

  11. 11.

    Wang SA, Hasserjian RP, Tam W, et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017;102:1352–60.

  12. 12.

    Schwaab J, Knut M, Haferlach C, et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015;94:233–8.

  13. 13.

    Rumi E, Milosevic JD, Casetti I, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013;31:e269–71.

  14. 14.

    Murati A, Gelsi-Boyer V, Adelaide J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia. 2005;19:1692–6.

  15. 15.

    Bousquet M, Quelen C, De Mas V, et al. The t(8;9)(p22; p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene. 2005;24:7248–52.

  16. 16.

    Hidalgo Lopez JE, Carballo-Zarate A, Verstovsek S, et al. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol. 2018;97:425–34.

  17. 17.

    Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535–40.

  18. 18.

    Zhou MH, Gao L, Jing Y, et al. Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol. 2012;91:1235–43.

  19. 19.

    Tirado CA, Chen W, Huang LJ, et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24; q11.2) in B-acute lymphoblastic leukemia. Leuk Res. 2010;34:1674–6.

  20. 20.

    Roberts KG, Gu Z, Payne-Turner D, et al. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol. 2017;35:394–401.

  21. 21.

    Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group. Blood. 2017;129:3352–61.

  22. 22.

    Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–15.

  23. 23.

    Borowitz MJ, Chan JKC, Downing JR, Le Beau MM, Arber D. B-lymphoblasticleukemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow SH, CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of Tumors of Haematopoietic and Lymphoid Tissue. Lyon: IARC; 2017.

  24. 24.

    Keane C, Henden A, Mills T, Wood P. Myeloid and lymphoid neoplasm with FGFR1 abnormality. Br J Haematol. 2009;145:440.

  25. 25.

    Wang W, Tang G, Kadia T, et al. Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11; q11)/BCR-FGFR1 Rearrangement. J Natl Compr Canc Netw. 2016;14:708–11.

  26. 26.

    Baer C, Muehlbacher V, Kern W, Haferlach C, Haferlach T. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. Haematologica. 2018.

Download references

Author information


  1. Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    • Guilin Tang
    • , Roberto N. Miranda
    • , Carlos Bueso-Ramos C
    •  & Sa A. Wang
  2. Department of Pathology, University of Chicago, Chicago, IL, USA

    • John Kennedy Sydney Sir Philip
    •  & Daniel A. Arber
  3. Department of Pathology, Boston Children Hospital, Boston, MA, USA

    • Olga Weinberg
  4. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA

    • Wayne Tam
    • , Elizabeth M. Margolskee
    •  & Attilio Orazi
  5. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

    • Sam Sadigh
    • , Jonathan I. Lake
    •  & Adam Bagg
  6. Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA

    • Heesun J. Rogers
    •  & Eric D. Hsi
  7. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    • Robert P. Hasserjian


  1. Search for Guilin Tang in:

  2. Search for John Kennedy Sydney Sir Philip in:

  3. Search for Olga Weinberg in:

  4. Search for Wayne Tam in:

  5. Search for Sam Sadigh in:

  6. Search for Jonathan I. Lake in:

  7. Search for Elizabeth M. Margolskee in:

  8. Search for Heesun J. Rogers in:

  9. Search for Roberto N. Miranda in:

  10. Search for Carlos Bueso-Ramos C in:

  11. Search for Eric D. Hsi in:

  12. Search for Attilio Orazi in:

  13. Search for Robert P. Hasserjian in:

  14. Search for Daniel A. Arber in:

  15. Search for Adam Bagg in:

  16. Search for Sa A. Wang in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Sa A. Wang.

Electronic supplementary material

About this article

Publication history